crisis

(redirected from vaso-occlusive crisis)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia.
Related to vaso-occlusive crisis: sickle-cell disease, acute chest syndrome, Sickle cell crisis
References in periodicals archive ?
It is the most common reported cause of death in patients hospitalized with vaso-occlusive crisis and is a significant risk factor for early mortality in these patients, accounting for 25% of premature deaths.
GlycoMimetics has selected vaso-occlusive crisis (VOC) of sickle cell disease as the first potential indication to explore with GMI-1070.
These same clinical signs and symptoms also feature prominently in vaso-occlusive crisis and as such make the diagnosis of osteomyelitis in SCD subjects sometimes difficult.
GlycoMimetics is studying vaso-occlusive crisis (VOC) of sickle cell disease, one of the most debilitating effects of sickle cell disease, where changes in blood protein cause red blood cells to become rigid and stick inside small blood vessels, causing blockages in blood flow and pain.
Vaso-occlusive crisis, one of the most severe complications of sickle cell disease, can result in acute ischemic tissue injury at one or more sites, with inflammation and pain of varying degrees of severity.
We are very pleased to partner with Pfizer for the advancement of GlycoMimetics' lead drug candidate, GMI-1070, which is initially being evaluated in patients with sickle cell disease experiencing vaso-occlusive crisis.
There are more than 75,000 hospitalizations per year associated with vaso-occlusive crisis in the U.
The article, "GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice," presents pre-clinical data supporting testing of GMI-1070 in clinical trials to treat patients with vaso-occlusive crisis of sickle cell disease.
One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease.
FDA Grants GMI-1070 Fast Track Designation for Treatment of Vaso-Occlusive Crisis of Sickle Cell Disease